

**Supporting Information**

**A Multifunctional Micropore-Forming Bioink with Enhanced Anti-Bacterial and Anti-Inflammatory Properties**


Mian Wang<sup>1#</sup>, Wanlu Li<sup>1#</sup>, Zeyu Luo<sup>1</sup>, Guosheng Tang<sup>1</sup>, Xuan Mu<sup>1</sup>, Xiao Kuang<sup>1</sup>, Jie Guo<sup>1</sup>, Zhibo Zhao<sup>1</sup>, Regina Sanchez Flores<sup>1</sup>, Zewei Jiang<sup>1</sup>, Liming Lian<sup>1</sup>, Julia Olga Japo<sup>1</sup>, Amir M. Ghaemmaghami<sup>2</sup>, Yu Shrike Zhang<sup>1\*</sup>

<sup>1</sup> Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA


<sup>2</sup> Immunology and Immuno-bioengineering Group, School of Life Science, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham NG7 2RD, UK

\*Correspondence address. Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA


E-mail: [yszhang@research.bwh.harvard.edu](mailto:yszhang@research.bwh.harvard.edu)




**Figure S1.** Photograph of the in-house-built handheld bioprinter.




**Figure S2.** (A) EDX spectrum of the AgGNRs. (B) EDX elemental mapping of the AgGNRs and the distributions of gold and silver elements.




**Figure S3.** Zeta potentials of AgGNRs and IL-4@AgGNRs.  $**P < 0.01$ ; one-way ANOVA (compared with the AgGNR control group);  $n = 3$ .




**Figure S4.** Gene expressions (*COX-2*, *TGF-β*, *CCL-2*, and *IL-6*) of MSCs encapsulated in GelMA, PGelDex, and IL-4@AgGNR-incorporated PGelDex constructs normalized to reference gene *RPL13A* in GelMA.



**Figure S5.** Gene expressions of MSCs encapsulated in GelMA, PGelDex, and IL-4@AgGNR-incorporated PGelDex constructs normalized to reference gene *GAPDH* in GelMA. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ; one-way ANOVA (C, compared with the GelMA control group); ### $P < 0.001$ ; one-way ANOVA (compared with the PGelDex group);  $n = 3$ .



**Figure S6.** Representative macrophage phenotype markers of THP-1 cells cultured in PGelDex, IL-4@AgGNR-incorporated PGelDex, MSC-encapsulated PGelDex, and MSC-IL-4@AgGNR-incorporated PGelDex constructs through a transwell assay. Relative mRNA expressions were normalized to reference gene *ACTB* in GelMA. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ; one-way ANOVA (compared with the PGelDex control group);  $n = 3$ .



**Figure S7.** Morphologies of GFP-HUVECs after 6 days of culture in the constructs bioprinted with (A) GelMA, (B) PGelDex, (C) IL-4@AgGNR-incorporated PGelDex bioinks.



**Table S1.** List of primer sequences used for qRT-PCR measurements of immunomodulatory gene expressions by the MSCs.

<b>Gene</b>	<b>Forward</b>	<b>Reverse</b>
<i>hCCL2</i>	AGGTGACTGGGGCATTGA	GCCTCCAGCATGAAAGTCTC
<i>hCSF-1</i>	TGGCGAGCAGGAGTATCAC	AGGTCTCCATCTGACTGTCAAT
<i>hCOX-2</i>	TGACCAGAGCAGGCAGATGAA	CCACAGCATCGATGTCACCATAG
<i>hTGF-<math>\beta</math></i>	AGCGACTCGCCAGAGTGGTTA	GCAGTGTGTTATCCCTGCTGTCA
<i>hTSG-6</i>	TCTGTGCTGCTGGATGGATG	TCCTTTGCGTGTGGGTTGTA
<i>hHMOX</i>	CTTCTTCACCTTCCCCAACA	AGCTCCTGCAACTCCTCAA
<i>hHGF</i>	GCTATCGGGTAAAGACCTACA	CGTAGCGTACCTCTGGATTGC
<i>IDO</i>	TTCAGTGCTTTGACGTCCTG	TGGAGGAACTGAGCAGCAT
<i>RPL13A</i>	CGAGGTTGGCTGGAAGTACC	CTTCTCGGCCTGTTTCCGTAG
<i>hGAPDH</i>	GTCTCCTCTGACTTCAACAGCG	ACCACCCTGTTGCTGTAGCCAA

**Table S2.** List of primer sequences used for qRT-PCR measurements of macrophage marker expressions by the THP-1 cells.

<b>Gene</b>	<b>Forward</b>	<b>Reverse</b>
<i>TNF<math>\alpha</math></i>	ATGAGCACTGAAAGCATGATCCGG	GCAATGATCCCAAAGTAGACCTGCCC
<i>IL-1<math>\beta</math></i>	ATGGCAGAAGTACCTAAGCTCGC	ACACAAATTGCATGGTGAAGTCAGTT
<i>iNOS</i>	ATTCAGGTACGCTGTGTTTGG	CATGGTGAACACGTTCTTGG
<i>IL-6</i>	GGAGACTTGCCTGGTGAAAA	AAAGCTGCGCAGAATGAGAT
<i>CD206</i>	GGGTTGCTATCACTCTCTATGC	TTTCTTGTCTGTTGCCGTAGTT
<i>Arg-1</i>	CACAGTCTGGCAGTTGGAAGC	CTTTGGCAGATATGCAGGGAG
<i>IL-10</i>	TACGGCGCTGTCATCGATT	GGCTTTGTAGATGCCTTTCTCTTG
<i>CCL22</i>	ATCGCCTACAGACTGCACTC	GACGGTAACGGACGTAATCAC
<i>hGAPDH</i>	GTCTCCTCTGACTTCAACAGCG	ACCACCCTGTTGCTGTAGCCAA
<i>ACTB</i>	ATTGCCGACAGGATGCAGAA	GCTGATCCACATCTGCTGGAA